Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18764298 | BIO-BASED EPOXY CHAIN EXTENDER AND PREPARATION METHOD THEREOF | July 2024 | January 2025 | Allow | 7 | 2 | 0 | No | No |
| 18747813 | 1,2,4-Oxadiazole Derivatives as Immunomodulators | June 2024 | February 2026 | Allow | 20 | 1 | 0 | No | No |
| 18660668 | Apoptosis Signal-Regulating Kinase 1 Inhibitors and Methods of Use Thereof | May 2024 | October 2025 | Allow | 17 | 0 | 0 | Yes | No |
| 18657122 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | May 2024 | July 2025 | Allow | 14 | 1 | 0 | No | No |
| 18615722 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | March 2024 | January 2026 | Allow | 22 | 1 | 0 | No | No |
| 18612147 | PIKFYVE KINASE INHIBITORS | March 2024 | March 2026 | Allow | 24 | 2 | 1 | No | No |
| 18426035 | NITRIC OXIDE RELEASING PRODRUGS OF MDA AND MDMA | January 2024 | June 2025 | Allow | 17 | 1 | 0 | Yes | No |
| 18405633 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | January 2024 | December 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18402325 | CROWN ETHER CARBENES AND METHODS OF USE | January 2024 | January 2025 | Allow | 13 | 1 | 0 | No | No |
| 18390071 | PROCESSES FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | December 2023 | June 2025 | Allow | 17 | 1 | 0 | No | No |
| 18524339 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | November 2023 | August 2024 | Allow | 9 | 0 | 0 | No | No |
| 18513752 | GLP-1 Receptor Agonists and Uses Thereof | November 2023 | January 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18384698 | 4,5-BIS(4-BROMOPHENYL)-1-HEXYL-2-(3,4-DIMETHOXYPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18383683 | 4-(2,4,5-TRIS(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)BUTANOIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 2 | 0 | 0 | No | No |
| 18379724 | 4-NITRO-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)BENZIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | December 2023 | Allow | 2 | 0 | 0 | No | No |
| 18475749 | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS | September 2023 | February 2025 | Allow | 17 | 1 | 0 | No | No |
| 18373241 | METHODS FOR CONVERTING CBD TO TETRAHYDROCANNABINOLS | September 2023 | November 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18242305 | CROWN ETHER AMINES AND METHODS OF USE | September 2023 | August 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18456819 | COMPOSITIONS AND METHODS FOR INHIBITING GROUP II INTRON RNA | August 2023 | May 2025 | Allow | 20 | 2 | 1 | No | No |
| 18448696 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | August 2023 | August 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18446640 | ANTI-INFLAMMATORY COMPOUNDS | August 2023 | December 2025 | Allow | 28 | 5 | 0 | No | No |
| 18363585 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | August 2023 | November 2024 | Allow | 16 | 2 | 0 | No | No |
| 18228192 | METHODS AND COMPOSITIONS FOR TERPENOID SYNTHESIS | July 2023 | June 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18226767 | PRODRUG COMPOUNDS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND METHODS OF SYNTHESIZING THE SAME | July 2023 | December 2024 | Abandon | 16 | 2 | 0 | Yes | No |
| 18351472 | CRYSTALS | July 2023 | April 2024 | Allow | 10 | 0 | 0 | No | No |
| 18347099 | ANTI-VIRAL COMPOUNDS | July 2023 | January 2026 | Allow | 30 | 1 | 0 | No | No |
| 18213019 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | June 2023 | July 2025 | Abandon | 25 | 2 | 0 | No | No |
| 18269109 | SYSTEM AND METHOD FOR PREPARING EPOXY CHLOROPROPANE | June 2023 | July 2024 | Allow | 12 | 1 | 0 | No | No |
| 18320906 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | May 2023 | September 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18316579 | TETRACYCLIC COMPOUNDS AND USES THEREOF | May 2023 | August 2024 | Allow | 15 | 1 | 0 | No | No |
| 18305418 | CANNABINOID FORMULATIONS AND DOSAGE | April 2023 | July 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18299442 | ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES | April 2023 | December 2024 | Allow | 20 | 2 | 1 | No | No |
| 18194155 | GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTS | March 2023 | January 2025 | Abandon | 21 | 2 | 0 | No | No |
| 18124856 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | March 2023 | March 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18188136 | METHODS FOR TREATING COVID-19 | March 2023 | February 2026 | Allow | 35 | 1 | 0 | Yes | No |
| 18170048 | CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE | February 2023 | July 2025 | Allow | 29 | 1 | 0 | No | No |
| 18110416 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | February 2023 | February 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18106713 | HEXASUBSTITUTED RADIALENE COMPOUNDS AND APPLICATIONS THEREOF | February 2023 | January 2026 | Allow | 35 | 1 | 0 | Yes | No |
| 18040365 | METHOD FOR PRODUCING COMPOUND | February 2023 | August 2025 | Allow | 30 | 0 | 0 | No | No |
| 18161603 | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | January 2023 | November 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 18158006 | COMPOUND OR SALT THEREOF, COMPOSITION, CHEMILUMINESCENCE METHOD, METHOD FOR MEASURING CHEMILUMINESCENCE SIGNAL, REAGENT, REAGENT KIT, AND METHOD FOR ASSAYING ANALYTE | January 2023 | February 2025 | Allow | 24 | 2 | 1 | No | No |
| 18005226 | 4-FURANAMIDES AND METHOD FOR THE PRODUCTION THEREOF | January 2023 | July 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 18152968 | METHOD FOR MANUFACTURING LOW-VISCOSITY HARDENER | January 2023 | December 2025 | Allow | 35 | 1 | 0 | No | No |
| 18150992 | ANTHELMINTIC AZA-BENZOTHIOPHENE AND AZA-BENZOFURAN COMPOUNDS | January 2023 | October 2025 | Allow | 34 | 1 | 0 | Yes | No |
| 18093773 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | January 2023 | June 2025 | Allow | 30 | 0 | 0 | No | No |
| 18147189 | NITRIC OXIDE RELEASING PRODRUGS OF MDA AND MDMA | December 2022 | October 2023 | Allow | 10 | 1 | 0 | Yes | No |
| 18066000 | Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof | December 2022 | May 2025 | Allow | 29 | 1 | 0 | No | No |
| 18063331 | COMPOUND AND POLYMER COMPOUND CONTAINING THE COMPOUND | December 2022 | July 2024 | Allow | 19 | 2 | 0 | Yes | No |
| 18061111 | TRANSITION METAL COMPLEXES COMPRISING CARBENE LIGANDS SERVING AS EMITTERS FOR ORGANIC LIGHT-EMITTING DIODES (OLED'S) | December 2022 | December 2025 | Abandon | 37 | 4 | 1 | No | No |
| 18073728 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | December 2022 | February 2024 | Allow | 14 | 1 | 0 | No | No |
| 18070408 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | November 2022 | April 2024 | Abandon | 16 | 1 | 0 | No | No |
| 17985415 | LIGANDS TO CEREBLON (CRBN) | November 2022 | June 2024 | Allow | 19 | 2 | 0 | Yes | No |
| 17982983 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | November 2022 | August 2023 | Allow | 10 | 0 | 0 | No | No |
| 17981695 | 1,2,4-Oxadiazole Derivatives as Immunomodulators | November 2022 | December 2023 | Allow | 14 | 1 | 0 | No | No |
| 17981201 | CROWN ETHER CARBENES AND METHODS OF USE | November 2022 | October 2023 | Allow | 12 | 1 | 0 | No | No |
| 17981162 | CROWN ETHER AMINES AND METHODS OF USE | November 2022 | June 2023 | Allow | 7 | 0 | 0 | No | No |
| 17922999 | CO-CRYSTAL OF KETOPROFEN, LYSINE AND GABAPENTIN, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USE | November 2022 | May 2025 | Allow | 31 | 0 | 0 | No | No |
| 17910682 | VIRAL INFECTION THERAPEUTIC | October 2022 | December 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17967599 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | October 2022 | February 2024 | Allow | 16 | 2 | 0 | Yes | No |
| 18046205 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | October 2022 | April 2024 | Allow | 18 | 1 | 0 | No | No |
| 17963823 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | October 2022 | November 2024 | Allow | 25 | 1 | 1 | No | No |
| 17782075 | METHOD FOR MANUFACTURING (2,2-DIMETHYL-1,3-DIOXOLAN-4-YL)METHANOL | October 2022 | November 2025 | Allow | 41 | 1 | 0 | No | No |
| 17950772 | METHODS AND COMPOSITIONS FOR TERPENOID TRICYCLOALKANE SYNTHESIS | September 2022 | January 2025 | Allow | 28 | 5 | 1 | No | No |
| 17946908 | Antibodies to Symmetrically Dimethylated Arginine Analytes and Use Thereof | September 2022 | April 2025 | Allow | 31 | 1 | 1 | No | No |
| 17931773 | Tripartite Androgen Receptor Eliminators, Methods and Uses Thereof | September 2022 | March 2025 | Allow | 30 | 3 | 1 | Yes | No |
| 17940287 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | September 2022 | August 2024 | Allow | 23 | 2 | 0 | No | No |
| 17910082 | Substituted Pyrimidines and Uses Thereof | September 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17905799 | COMPOUND PRODUCING METHOD, AND COMPOUND | September 2022 | February 2023 | Allow | 5 | 0 | 0 | No | No |
| 17902618 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | September 2022 | April 2024 | Allow | 20 | 2 | 0 | No | No |
| 17929644 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | September 2022 | January 2026 | Allow | 41 | 1 | 1 | No | No |
| 17820845 | CANNABIS SPECIES AS INDUSTRIAL CHEMICAL FEEDSTOCKS | August 2022 | January 2025 | Abandon | 29 | 4 | 1 | No | No |
| 17819089 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | August 2022 | November 2023 | Abandon | 15 | 1 | 0 | No | No |
| 17798282 | DRUG FOR TREATING CORONAVIRAL AND RETROVIRAL INFECTIONS AND HEPATITIS C | August 2022 | October 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17760309 | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | August 2022 | August 2025 | Allow | 36 | 1 | 0 | No | No |
| 17816349 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | July 2022 | January 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 17795985 | COMPOUNDS AND USES THEREOF | July 2022 | September 2025 | Allow | 38 | 1 | 0 | No | No |
| 17758683 | PROCESS FOR PREPARING CYCLIC CARBONATES WITH AN EXOCYCLIC VINYLIDENE GROUP | July 2022 | August 2025 | Allow | 37 | 0 | 0 | No | No |
| 17854630 | TREATMENT OF SKIN DISORDERS | June 2022 | August 2025 | Allow | 37 | 1 | 1 | Yes | No |
| 17841570 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | June 2022 | November 2023 | Allow | 17 | 1 | 0 | No | No |
| 17785162 | PEGYLATED ICD INDUCER-IDO INHIBITOR NANOCONJUGATE, AND PREPARATION METHOD AND USE THEREOF | June 2022 | September 2025 | Allow | 40 | 1 | 0 | No | No |
| 17831592 | Benzoimidazole Derivatives As Anticancer Agents | June 2022 | August 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17756626 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | May 2022 | September 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17780268 | NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR | May 2022 | November 2025 | Allow | 41 | 0 | 1 | Yes | No |
| 17779703 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | May 2022 | December 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17750220 | PYRROLIDINE DERIVATIVES | May 2022 | July 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17777767 | BIPHENYL FLUORINE DOUBLE BOND DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | May 2022 | July 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17777704 | SULFONYLUREA RING SUBSTITUTED MONOCYCLIC beta-LACTAM ANTIBIOTICS | May 2022 | November 2025 | Allow | 42 | 2 | 0 | Yes | No |
| 17743534 | PROCESS FOR PREPARING ESTERS OF N-ACYLATED AMINO ACIDS WITH ACID-LABILE KETO PROTECTIVE GROUP FUNCTIONS | May 2022 | November 2023 | Abandon | 18 | 1 | 0 | No | No |
| 17744470 | CATIONIC ANTIMICROBIAL OLIGO-GUANIDINIUM DENDRIMERS AND COMPOSITIONS | May 2022 | December 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17732659 | Cannabidiol (CBD) as Chemical for Treating Aging-related Degenerative Diseases and Promoting Health Aging | April 2022 | February 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17720643 | EPOXY REACTIVE DILUENT AND MANUFACTURING METHOD THEREFOR | April 2022 | September 2025 | Allow | 41 | 1 | 1 | No | No |
| 17713221 | GLYCOPYRROLATE SALTS | April 2022 | September 2023 | Allow | 18 | 2 | 0 | No | No |
| 17701404 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | March 2022 | May 2023 | Allow | 14 | 1 | 0 | No | No |
| 17692113 | ELECTRONIC DEVICES USING ORGANIC SMALL MOLECULE SEMICONDUCTING COMPOUNDS | March 2022 | January 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17679659 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | February 2022 | January 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17587268 | NERVE DAMAGE PREVENTING AND NERVE PROTECTING COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND THEIR USE | January 2022 | February 2024 | Allow | 25 | 2 | 1 | No | No |
| 17630291 | COMPOUNDS FOR USE IN THE TREATMENT OF LIVER DISEASE | January 2022 | September 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17574820 | NLRP3 INFLAMMASOME INHIBITORS | January 2022 | March 2024 | Allow | 26 | 1 | 0 | No | No |
| 17570420 | METHOD FOR PRODUCING FISETIN OR FISETIN DERIVATIVES | January 2022 | November 2022 | Allow | 10 | 0 | 0 | No | No |
| 17566248 | ATYPICAL COUPLING METHOD FOR THE PREPARATION OF 1,2-DI(THIOPHEN-2-YL)ETHENE-1,2-DIOL COMPOUNDS VIA A CU(II) CATALYST | December 2021 | April 2023 | Allow | 15 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner COUGHLIN, MATTHEW P.
With a 55.6% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 25.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner COUGHLIN, MATTHEW P works in Art Unit 1626 and has examined 1,229 patent applications in our dataset. With an allowance rate of 70.5%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 26 months.
Examiner COUGHLIN, MATTHEW P's allowance rate of 70.5% places them in the 33% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by COUGHLIN, MATTHEW P receive 1.68 office actions before reaching final disposition. This places the examiner in the 34% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by COUGHLIN, MATTHEW P is 26 months. This places the examiner in the 75% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +14.7% benefit to allowance rate for applications examined by COUGHLIN, MATTHEW P. This interview benefit is in the 54% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 27.4% of applications are subsequently allowed. This success rate is in the 48% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 51.7% of cases where such amendments are filed. This entry rate is in the 78% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 71.0% of appeals filed. This is in the 58% percentile among all examiners. Of these withdrawals, 77.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 61.6% are granted (fully or in part). This grant rate is in the 66% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 6.8% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.4% of allowed cases (in the 64% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.